Previous 10 | Next 10 |
The Nasdaq has halted trading of Reata Pharmaceuticals' (NASDAQ:RETA) common stock. The FDA's Cardiovascular and Renal Drugs Advisory Committee is meeting to review the Company’s New Drug Application (NDA) for bardoxolone methyl for the treatment of patients with chronic kidney di...
Reata Pharmaceuticals, Inc . (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, announced today that Nasdaq has halted trading of the Company’s common stock. The U.S. Food and Drug Admini...
New York, New York--(Newsfile Corp. - December 7, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) common stock. Reata is a clinical-stage drug company. Reata's lead program is developing the drug ...
Easing fears about the Omicron variant led to a general rally on Monday. However, vaccine stocks were left out of the upswing, dropping precipitously as their Omicron premium evaporated amid a critical tweet from a high-profile politician. The overall decline in the sector included double-dig...
Monday was one of the worst days in the history of Reata Pharmaceuticals ' (NASDAQ: RETA) stock. After trading in the shares was halted in the morning due to volatility, they closed the session down by nearly 38%. There was good reason for the volatility, and for that monster price ...
Gainers: Del Taco Restaurants (NASDAQ:TACO) +66%. Insignia Systems (NASDAQ:ISIG) +64%. Adicet Bio (NASDAQ:ACET) +37%. Cloopen Group (NYSE:RAAS) +24%. eFFECTOR Therapeutics (NASDAQ:EFTR) +20%. Recruiter (NASDAQ:RCRT) +21%. Edgewise Therapeutics (NASDAQ:EWTX) +21%. Liberty TripAdvisor (NASDAQ:L...
Reata Pharmaceuticals (RETA -37.2%) is trading sharply lower in morning hours after the FDA released briefing documents ahead of the Advisory Committee meeting scheduled for Dec. 08 for the company’s marketing application for the kidney disease drug, bardoxolone methyl. With ...
The FDA has granted Fast Track Designation to Reata Pharmaceuticals (NASDAQ:RETA) for omaveloxolone for Friedreich’s ataxia. The company plans to submit an NDA in Q1 2022. Friedreich’s ataxia is a rare, genetic degenerative neuromuscular disorder usually diagnosed during a...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) h...
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...